Susvimo has the same active ingredient as Roche's big-selling therapy Lucentis (ranibizumab), a VEGF inhibitor administered once a month that has been approved by the FDA since 2006 for wet AMD.

The companion product – Susvimo – is an implantable treatment based on ranibizumab that can extend the time between treatments to six months or more and was approved by the FDA last October.

Penmenvy (meningococcal Groups A, B, C, W, and Y vaccine) Meningococcal vaccine For active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y in ...

The companies agreed to share profits for the therapy equally in the U.S. and Europe, but Roche will have exclusive rights to commercialization in the rest of the world. ZURICH (Reuters) -Roche ...

At close: March 13 at 5:30:51 PM GMT+1 ...

Two companies have received approved for a generic of the 2.5 mg tablet of anticoagulant rivaroxaban, which is used to reduce the risk of stroke and deep vein thrombosis.

Ramiro Ribeiro, MD, PhD, shares insights from the ongoing research tyrosine kinase inhibitors for AMD and DME.